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Several randomized clinical trials have evaluated 
the efficacy of prophylactic magnesium (Mg) 
supplementation in prevention of post-operative atrial 
fibrillation (POAF) in patients undergoing cardiac artery 
bypass grafting (CABG). We aim to determine the 
role of prophylactic Mg in 3 settings (intraoperative, 
postoperative, intraoperative + postoperative) in 
prevention of POAF. 
© 2016 Lehigh Valley Health Network
A systemic literature search was performed (until 
October 20, 2015) using PubMed, EMBASE, Web 
of Science, and Cochrane Central Register of 
Controlled Trials to identify trials evaluating Mg 
supplementation post CABG (figure 1). Primary 
outcome of our study was reduction in the POAF. 
For each study, the incidence of atrial fibrillation 
in both the intervention and placebo groups 
was extracted to calculate odd ratio and 95% 
confidence intervals (CIs).
We included a total of 2,973 participants (1,471 in the Mg group and 1,502 in the placebo group) enrolled 
in 23 randomized controlled trials. By using random-effects models, pooled analysis demonstrated 
no significant reduction in POAF (OR 0.81; 95% CI, 0.64-1.02; p = 0.08) in Mg group as compared to 
placebo. However, there was reduction in POAF in the group that received prophylactic Mg postoperatively 
(OR 0.66; 95% CI 0.44-0.99; p = 0.04) with no significant heterogeneity. Number needed to treat in our 
study = 13 (95% CI 7.04-81.34).
In nine trials that evaluated prophylactic intraoperative Mg supplementation, 27% patients had POAF in 
the intraoperative Mg arm versus 26% in the control arm with no significant reduction in POAF (OR 0.88; 
95% CI: 0.58 - 1.33; p=0.53). 
In seven trials evaluated a combined intra and postoperative magnesium supplementation approach.  
There was no reduction in POAF (29% and 31% in Mg arm versus control arm; OR=0.87; 95% CI=0.60 - 
1.27; p=0.48) (figure 2).
Prophylactic postoperative Mg supplementation resulted in a 
lower incidence of POAF in patients undergoing CABG. 
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Heterogeneity. Tau2 = 0.13: Chi2 = 13.44, df = 8 (P = 0.10); I2 = 40%






































































Heterogeneity Tau2 = 0.05; Chi2 = 7.29, df = 6 (P = 0.29); I2 = 18%



























































Heterogeneity. Tau2 = 0.11; Chi2 = 10.78, df = 6 (P = 0.10); I2 = 44%
Test for overall effect: Z = 0.71 (P = 0.48)
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Figure 2: Forest plot evaluating the efficacy of prophylactic magnesium (Mg) supplementation in prevention of post-
operative atrial fibrillation (POAF) in patients undergoing cardiac artery bypass grafting (CABG).
Figure 1: PRISMA Statement
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